BioCanRx invests $10 million in promising new cancer immunotherapy research and biomanufacturing
(BioCanRx - Canada's Immunotherapy Network) BioCanRx, Canada's Immunotherapy Network, announces funding of $10M for 14 cancer immunotherapy research projects and eight core and biomanufacturing facilities. In addition to BioCanRx's investment, partner contributions of $16.5M increase the investment in Canadian translational cancer immunotherapy research and manufacturing to $26.5M. Projects include cross-disciplinary teams working on new, rational combination approaches and unique cell, vaccine/virus-based and antibody immunotherapies. Investments in Canada's biomanufacturing capacity and point-of-care cell manufacturing will enhance access to life-saving therapies.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news
More News: Canada Health | Cancer | Cancer & Oncology | Cancer Vaccines | Funding | Immunotherapy | International Medicine & Public Health | Science | Vaccines